Abstract 2336P
Background
Epithelial-mesenchymal transition (EMT) is one of the major molecular mechanisms inducing tumor invasion and metastasis. Various MicroRNAs (miRNAs) have been shown to be involved in EMT. MiR-155 is consistently up-regulated in non-small cell lung cancer and is associated with poor overall survival. Whether miR-155 regulates EMT in lung cancer cells remains unclear.
Methods
We first transfected plasmid containing miR-155 into H1299 and A549 cells and established H1299-miR-155 and A549-miR-155 cells. Western blotting was done to demonstrate E-cadherin, vimentin, and Quaking (QKI) expression in H1299-miR-155 and A549-miR-155 cells. Invasion and migration assay were performed in H1299-miR-155 and A549-miR-155 cells. We then constructed p-mcherry plasmids that contain miR-155 and a p-Luc-QKI-3’UTR reporter plasmid. Luciferase assay was done to demonstrate whether miR-155 binds to the QKI 3’UTR.
Results
Quantitative RT-PCR showed that QKI expression was downregulated in H1299-miR-155 and A549-miR-155 cells. Western Blotting showed decreased E-cadherin and increased vimentin expression in H1299 and A549 cells after miR-155 transfection. Western blotting also showed decreased QKI expression in H1299 and A549 cells after miR-155 transfection. Migration assay showed that the number of migrated cells significantly increased after miR-155 transfection in H1299 and A549 cells. Invasion assay showed that the number of invaded cells also significantly increased after miR-155 transfection in H1299 and A549 cells. We constructed p-mcherry plasmids that contain miR-155 and a p-Luc-QKI-3’UTR reporter plasmid. Luciferase assay showed that miR-155 represses the activity of p-Luc-QKI-3’UTR. We then mutated the miR-155 binding site in the QKI 3’UTR to confirm that repression of the mRNA levels is induced by the binding of miR-155 to the QKI 3’UTR.
Conclusions
MiR-155 overexpression regulates EMT through repressing QKI in lung cancer cells. Repression of QKI is induced by the binding of miR-155 to the QKI 3’UTR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16